98 related articles for article (PubMed ID: 24804936)
1. Preanalytical factors of importance for measurement of Chromogranin A.
Pedersen L; Nybo M
Clin Chim Acta; 2014 Sep; 436():41-4. PubMed ID: 24804936
[TBL] [Abstract][Full Text] [Related]
2. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
3. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
4. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
5. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
6. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
[TBL] [Abstract][Full Text] [Related]
7. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
9. Plasma chromogranin A after severe burn trauma.
Lindahl AE; Low A; Stridsberg M; Sjöberg F; Ekselius L; Gerdin B
Neuropeptides; 2013 Jun; 47(3):207-12. PubMed ID: 23206950
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin-A levels measured with automated immunoassay.
Gruson D; Lepoutre T; Smits F
Int J Biol Markers; 2015 Feb; 30(1):e132-5. PubMed ID: 24903589
[TBL] [Abstract][Full Text] [Related]
11. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CisBio ELISA for Chromogranin A Measurement.
Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
[TBL] [Abstract][Full Text] [Related]
14. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
16. A chromogranin A ELISA absent of an apparent high-dose hook effect observed in other chromogranin A ELISAs.
Erickson JA; Grenache DG
Clin Chim Acta; 2016 Jan; 452():120-3. PubMed ID: 26554519
[TBL] [Abstract][Full Text] [Related]
17. Decreased plasma Chromogranin A361-372 (Catestatin) but not Chromogranin A17-38 (Vasostatin) in female dogs with bacterial uterine infection (pyometra).
Jitpean S; Stridsberg M; Pettersson A; Höglund OV; Holst BS; Hagman R
BMC Vet Res; 2015 Jan; 11():14. PubMed ID: 25636335
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
19. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
Sciarra A; Di Silverio F; Autran AM; Salciccia S; Gentilucci A; Alfarone A; Gentile V
Urol Int; 2009; 82(2):147-51. PubMed ID: 19321999
[TBL] [Abstract][Full Text] [Related]
20. Spurious increase in serum chromogranin A: the role of heterophilic antibodies.
Giovanella L; Ceriani L
Clin Chem Lab Med; 2010 Oct; 48(10):1497-9. PubMed ID: 20666696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
